A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the Treatment of Metastatic Breast Cancer.

Trial Profile

A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the Treatment of Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Octreotide (Primary) ; Capecitabine; Lapatinib
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 31 Jul 2017 to 30 Sep 2017.
    • 31 Jul 2017 Planned primary completion date changed from 31 Jul 2017 to 30 Sep 2017.
    • 06 Jun 2017 Planned End Date changed from 31 May 2017 to 31 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top